Melanoma Research

Skip Navigation LinksHome > October 2014 - Volume 24 - Issue 5 > Activity of trametinib in K601E and L597Q BRAF mutation-posi...
Melanoma Research:
doi: 10.1097/CMR.0000000000000099
Short Communications

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Bowyer, Samantha E.a,*; Rao, Aparna D.c,*; Lyle, Megane; Sandhu, Shahneenc; Long, Georgina V.e,f; McArthur, Grant A.c,d; Raleigh, Jeanette M.c; Hicks, Rodney J.c,d; Millward, Michaela,b

Collapse Box

Abstract

BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy and safety in four patients with BRAF K601E and one patient with L597Q mutation-positive metastatic melanoma treated with the MEK inhibitor trametinib. Three patients achieved a RECIST partial response, including the patient with an L597Q mutation. Paired biopsies available in one of the five patients showed reduced phospho-ERK signalling and this corresponded to a metabolic response on 18F-fluorodeoxyglucose-PET scanning. Trametinib toxicity was manageable. Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.